Press Releases August 31, 2026 04:09 PM

SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026

SI-BONE to present at Morgan Stanley 24th Global Healthcare Conference detailing advancements in procedural bone health solutions

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
SIBN

SI-BONE, Inc., a Nasdaq-listed company specializing in procedural solutions for compromised bone, will participate in the Morgan Stanley 2026 Global Healthcare Conference with a fireside chat to discuss its technology platform and recent clinical advancements targeting spinopelvic anatomy and low-density bone challenges.

SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026
SIBN
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • SI-BONE is a leader in developing biomechanical procedural solutions for compromised bone, particularly focused on spinopelvic anatomy.
  • The company has supported over 150,000 procedures since 2009 and is backed by robust clinical evidence including randomized controlled trials and peer-reviewed publications.
  • Participation in a major healthcare conference highlights ongoing investor relations efforts and potential to showcase new technologies targeting clinical adjacencies.

SANTA CLARA, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Monday, September 14, 2026, at 8:30 a.m. Pacific Time/ 11:30 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by registering at this link: SI-BONE, Inc. - 1774169. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in developing procedural solutions to address clinical challenges associated with compromised bone. With expertise in biomechanical design and anatomy specific innovation, SI-BONE has built a technology platform with market-leading applications centered on the spinopelvic anatomy. SI-BONE continues to leverage the deep experience in addressing the challenges of low-density bone in the sacrum to develop unique technologies that are targeting new clinical adjacencies to help improve outcomes for patients with compromised bone. Since 2009, SI-BONE has supported physicians in performing a total of over 150,000 procedures. A unique body of clinical evidence supports the use of SI-BONE's technologies, including four randomized controlled trials and over 190 peer reviewed publications.

For additional information on the company or the products, including risks and benefits, please visit www.si-bone.com.

SI-BONE® is a registered trademark of SI-BONE, Inc. ©2026 SI-BONE, Inc. All Rights Reserved.

Investor Contact

Saqib Iqbal
VP, FP&A, and Investor Relations
investors@SI-BONE.com


Risks

  • Clinical adoption of SI-BONE's technologies depends on continued validation and physician acceptance, which may face challenges.
  • The company's growth prospects may be influenced by competition and advancements in alternative procedural solutions for bone health.
  • Market reception might be affected by broader healthcare sector conditions and regulatory developments impacting medical devices and surgical innovations.

More from Press Releases

Lifecore Biomedical Signs Agreement for Commercial Site Transfer Supporting Global Pharmaceutical Company Sep 2, 2026 uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease Sep 2, 2026 Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential Sep 2, 2026 Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference Sep 2, 2026 Aeluma to Announce Fourth Quarter and Fiscal Year 2026 Financial Results on September 16, 2026 Sep 2, 2026